[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Downes KA, Goldblum JR, Montgomery EA, Fisher C: Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases. Mod Pathol; 2001 Mar;14(3):179-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases.
  • Pleomorphic liposarcoma is a variant of liposarcoma defined morphologically by the presence of pleomorphic lipoblasts.
  • Nineteen pleomorphic liposarcomas were studied.
  • Unequivocal pleomorphic lipoblasts were required for inclusion.
  • In each case, the following features were noted: tumor site; tumor size; tumor depth; predominant histologic pattern (epithelioid or malignant fibrous histiocytoma [MFH]-like); extent of necrosis (absent, less than 15%, or at least 15%); mitotic counts; treatment and clinical follow-up.
  • Predominant pattern was epithelioid in 7 and MFH-like in 12.
  • All patients were treated surgically; 10 patients received adjuvant chemotherapy and/or radiation therapy.
  • Metastases developed in eight patients (range, 4--48 mo; mean, 19.5 mo; median, 11.5 mo), most commonly to the lungs.
  • In conclusion, pleomorphic liposarcoma is a rare tumor of adulthood that occurs most commonly in the deep, soft tissues of the extremities.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Necrosis. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11266523.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Quadros CA, Vasconcelos A, Andrade R, Ramos RS, Studart E, Nascimento G, Trajano A: Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma. Int Semin Surg Oncol; 2006;3:18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma.
  • This article is a case report of a high grade, radio-induced, breast malignant fibrous histiocytoma (undifferentiated high grade pleomorphic sarcoma), which developed in a 44-year old female, seven years after breast conservative surgery and radiotherapy for a T1N0M0 invasive left breast ductal carcinoma.
  • Neoadjuvant chemotherapy was performed with epirubicin and ifosfamide.
  • Extended radical surgery according to oncological standards and soft tissue reconstruction were carried out.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2068-75 [10070313.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3378-83 [11013278.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):66-72 [7834431.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):356-8 [12383902.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1832-40 [12673708.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):856-63 [15981282.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7 [1648044.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • (PMID = 16824232.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1538603
  •  go-up   go-down


3. Maki RG: Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist; 2007 Aug;12(8):999-1006
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objective. In the era of oral molecular kinase inhibitors, cytotoxic chemotherapy agents are somewhat overlooked, but remain the backbone of treatment for most cancers.
  • Patients with non-gastrointestinal stromal tumor sarcomas, such as leiomyosarcoma, liposarcoma, and undifferentiated high-grade pleomorphic sarcoma (formerly called malignant fibrous histiocytoma), have received doxorubicin and ifosfamide as the backbone of their treatment for over 15 years or more.
  • Results. Activity of gemcitabine and docetaxel is observed in leiomyosarcoma and undifferentiated high-grade pleomorphic sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Sarcoma / pathology. Taxoids / therapeutic use
  • [MeSH-minor] Drug Synergism. Humans


Advertisement
4. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Mevio E, Sbrocca M, Gorini E, Artesi L, Mullace M, Castelli A, Migliorini L: Malignant fibrous histiocytoma of the pharynx. Acta Otorhinolaryngol Belg; 2003;57(1):79-81
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the pharynx.
  • Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life, but is relatively uncommon in the head and neck region.
  • That region has been reported to be the origin of malignant fibrous histiocytoma in 3-10% of cases.
  • Histologically it is sometimes hard to distinguish this tumor from some sarcomas and pleomorphic carcinomas.
  • The treatment of choice is a large surgical resection, while radiotherapy and chemotherapy are reserved for recurrences.
  • The authors present a case of oropharyngeal malignant fibrous histiocytoma.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12642957.001).
  • [ISSN] 0001-6497
  • [Journal-full-title] Acta oto-rhino-laryngologica Belgica
  • [ISO-abbreviation] Acta Otorhinolaryngol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


6. Eguíluz Lumbreras P, Palacios Hernández A, Heredero Zorzo O, García García J, Cañada de Arriba F, Pérez Herrero F, Gómez Zancajo R: Retroperitoneal malignant fibrous histiocytoma: case report. Arch Esp Urol; 2010 Jul-Aug;63(6):477-9
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal malignant fibrous histiocytoma: case report.
  • OBJECTIVE: We present the case of a big retroperitoneal tumor that received the pathologic diagnosis of malignant fibrous histiocytoma.
  • We also review the diagnostic and therapeutic features of this disease in the current literature.
  • Pathology reportes malignant fibrous histiocytoma of the storiform-pleomorphic type, with hyaline degeneration foci (stadium pT2B).
  • The surgical treatment is still the only therapy with healing possibilities.
  • Adjuvant treatments through radiotherapy and/or chemotherapy are brought into question.
  • [MeSH-major] Histiocytoma, Malignant Fibrous. Retroperitoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20820088.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Hoshi M, Takami M, Ieguchi M: Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. Radiat Med; 2008 Oct;26(8):499-503
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
  • We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously.
  • Although these metastases responded well to systemic chemotherapy, brain metastases newly appeared and caused the death of the patient.
  • These findings demonstrate that individual sarcomatous metastatic organs exhibit different sensitivities to chemotherapy.
  • It is suggested that the blood-brain barrier may play an important role in sensitivity to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Brain Neoplasms / drug therapy. Histiocytoma, Malignant Fibrous / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Acetabulum. Bone and Bones / drug effects. Brain / drug effects. Doxorubicin / administration & dosage. Forearm. Humans. Ifosfamide / administration & dosage. Lung / drug effects. Male. Middle Aged


8. Dilek TU, Dilek S, Pata O, Tataroglu C, Tok E: Malignant fibrous histiocytoma of the ovary: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:352-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the ovary: a case report.
  • Malignant fibrous histiocytoma is the most common type of soft tissue sarcoma in adults.
  • Primary malignant fibrous histiocytoma of the ovary is extremely rare, with only three previously reported cases.
  • We reported a rare and uncommon localization of malignant fibrous histiocytoma in a 22-year-old woman.
  • She was referred for adjuvant chemotherapy to our center with the diagnosis of storiform-pleomorphic malignant fibrous histiocytoma.
  • A left adnexal mass was detected by computed tomography of the lower abdomen.
  • Histopathologic examination revealed inflammatory, malignant fibrous histiocytoma.
  • The management of malignant fibrous histiocytoma is controversial because of the heterogenous nature of the disease.
  • Resection of all macroscopic disease is independently associated with improved disease-specific survival, and adjuvant chemotherapy for nonmyxoid variants could be acceptable alternatives if the surgical margins are tumor free.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Humans. Reoperation

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515621.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Kariya S, Aoji K, Kuyama K, Akagi H, Fukazawa M, Nishizaki K: Malignant fibrous histiocytoma of the parotid gland. Auris Nasus Larynx; 2003 Aug;30(3):315-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the parotid gland.
  • Primary malignant fibrous histiocytoma (MFH) arising in a major salivary gland is rare.
  • We encountered a case of MFH affecting the parotid gland.
  • The patient was a 54-year-old man diagnosed as having pleomorphic type of MFH after extended total parotidectomy.
  • Accordingly treatment consisted in the resection of MFH and radiotherapy in combination with chemotherapy using carboplatin (CBDCA).
  • This postoperative therapy was effective in controlling the growth of the remaining tumor tissue.
  • Our literature review yielded 17 cases of parotid MFH and the 2-year survival rate was 33%.
  • [MeSH-major] Histiocytoma, Benign Fibrous. Parotid Gland. Salivary Gland Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927301.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


10. Macák J, Smardová J, Zavrelová I, Vránová V, Kuglík P: Malignant fibrous histiocytoma of the parotid gland. Cesk Patol; 2007 Oct;43(4):148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the parotid gland.
  • We described a rare malignant fibrous histiocytoma of the parotid gland (MFH) in a 63-year-old woman.
  • The histology revealed a storiform-pleomorphic type of MFH with high mitotic rate.
  • The patient died shortly after the beginning of chemotherapy.
  • In view of short course of disease we lack the data about the influence of the non-mutated p53 gene on the prognosis and therapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188922.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


11. Wang BG, Liang H, Cui QH, Wang JC, Liu JZ: [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases]. Zhonghua Zhong Liu Za Zhi; 2004 Jun;26(6):373-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases].
  • OBJECTIVE: To investigate the diagnosis and treatment of malignant fibrous histiocytoma of the retroperitoneum (MFHR).
  • METHODS: The clinicopathological features, treatment and prognosis of 31 patients with MFHR were retrospectively analyzed.
  • The histopathologic types of the tumor were inflammatory, storiform-pleomorphic, myxoid and giant cell in 16, 10, 4 and 1 cases.
  • The overall survival rate of 1-, 3- and 5-year was 61.3% +/- 9.8%, 31.6% +/- 11.3% and 21.1% +/- 11.4% with a median survival time of 17.0 +/- 6.3 months.
  • Postoperative radiotherapy of 20 - 45 Gy was able to prolong the median survival from 12.1 +/- 11.6 months of surgery alone to 26.4 +/- 22.0 months of surgery plus postoperative radiotherapy though without statistical significance (P = 0.051).
  • Postoperative CHOP chemotherapy was not shown to be beneficial.
  • CONCLUSION: Chemotherapy remains the important method of cure.
  • The survival in patients with MFHR might be improved by complete resection combined with chemotherapy or/and radiotherapy.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatectomy. Postoperative Period. Prednisone / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Splenectomy. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15312351.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Shinozaki T, Kato K, Watanabe H, Yanagawa T, Ahmed AR, Takagishi K: Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue. J Orthop Sci; 2001;6(4):339-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue.
  • We prospectively followed 32 patients with soft-tissue malignant fibrous histiocytoma (MFH).
  • Parameters were age; sex; tumor size, location, and depth; operative method; chemotherapy; radiotherapy; and histology.
  • Patients with recurrence or metastases due to MFH within 6 months after the initial operation were separated from those without these characteristics by discriminant analysis with statistically significant difference.
  • Male patients with deep-seated storiform-pleomorphic type MFH, receiving less comprehensive surgery, had the greatest risk of local recurrence or early metastases.
  • Discriminant analysis to separate patients with MFH recurrence or metastases within 6 months after the initial operation from those without these characteristics is worthwhile for prognostic assessment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11479763.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


13. Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, Steinau HU: MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients. Langenbecks Arch Surg; 2009 Mar;394(2):313-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.
  • BACKGROUND: Undifferentiated pleomorphic sarcoma/NOS (not otherwise specified; former pleomorphic and storiform MFH) of the extremities is a common malignant soft tissue tumor in adults.
  • The objective of this study is to determine prognostic factors for the outcome after surgical treatment with respect to the recent developments in classification.
  • METHODS: From 1996 to 2004, 140 undifferentiated pleomorphic sarcomas/NOS were identified out of 1,200 soft tissue sarcomas of the extremities that were treated at our institution and recorded in a prospective database.
  • All tumors were retrospectively analyzed regarding prognostic factors of the disease, including patient's background (primary or recurrent), histological grade (G2/G3), adjuvant chemotherapy and radiotherapy, size (T1-2) and depth of the tumor, and surgical margins (R0, R1, R2).
  • CONCLUSIONS: In terms of OS and ILR, primary or recurrence, negative surgical margins, size and grading had a highly significant influence, whereas the site of surgery and adjuvant chemotherapy, adjuvant radiation and tumor depth did not.
  • Prognosis for patients with undifferentiated pleomorphic sarcoma of the extremities depends predominantly on adequate wide resection of the primary tumor.
  • [MeSH-major] Extremities / surgery. Histiocytoma, Malignant Fibrous / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2719-25 [12860950.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):391-405 [8604805.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Chirurg. 1993 Jul;64(7):517-26 [8375201.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 2004 Dec;33(12):602-8 [15641745.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] J Natl Cancer Inst. 1989 Oct 4;81(19):1496-9 [2778839.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):510-5 [12592363.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] Pathologe. 1996 Mar;17(2):116-21 [8650138.001]
  • [Cites] Am J Clin Pathol. 1998 Nov;110(5):660-70 [9802353.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):390-6 [3052763.001]
  • [Cites] Bull Cancer. 2004 Nov;91(11):853-60 [15582889.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Pathol Int. 2002 Sep;52(9):595-606 [12406189.001]
  • [Cites] Plast Reconstr Surg. 2004 Jan;113(1):222-30; discussion 231-2 [14707640.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Chirurg. 1988 Apr;59(4):265-71 [3383685.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1340-5 [15446553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6 [12601173.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):445-53 [9230909.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer. 1977 Apr;39(4):1672-85 [192434.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Praxis (Bern 1994). 1998 Aug 19;87(34):1061-5 [9757789.001]
  • (PMID = 18584203.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Shioya T, Yuzuriha R, Maejima K, Mizutani S, Nambu K, Hoshino A, Shibuya T, Tokunaga A, Matsumoto K, Tajiri T: Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy. Clin J Gastroenterol; 2008 Oct;1(3):122-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy.
  • Malignant fibrous histiocytoma of the liver is an extremely rare tumor.
  • Histopathologically, the tumor was diagnosed as a primary storiform-pleomorphic-type malignant fibrous histiocytoma of the liver.
  • One year after the radical operation, the patient developed recurrences in other organs.
  • She received 17 cycles of chemotherapy with etoposide, ifosfamide, and cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1992 Sep;21(3):290-2 [1328016.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):620-3 [17085355.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):386-91 [10390563.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W481-9 [17056878.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1331-9 [15446552.001]
  • (PMID = 26193650.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemotherapy / Liver / Malignant fibrous histiocytoma / Sarcoma / Surgery
  •  go-up   go-down


15. Jin GP, Zhao M, Qi JX, Jiang HG, Yu SG: [Malignant fibrous histiocytoma of head and neck: clinical analysis of 21 cases]. Ai Zheng; 2003 May;22(5):523-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of head and neck: clinical analysis of 21 cases].
  • BACKGROUND & OBJECTIVE: Malignant fibrous histiocytoma (MFH) is a type of pleomorphic neoplastic diseases with complex pathological structure.
  • This study was designed to investigate the clinical and pathological features and improve the diagnosis and treatment.
  • METHODS: To summarize and analyze the clinical experiences of 21 cases of MFH at head and neck proved histologically from June 1984 to June 1999 treated in Department of Head and Neck Surgery, Henan Tumor Hospital.
  • CONCLUSION: MFH at head and neck region is a kind of malignant disease with high recurrent rate and the cervical lymph node metastasis rate was 57.1%.
  • Amplified radical surgery is the first choice of treatment.
  • Radiotherapy alone or chemotherapy alone is not effective to MFH of head and neck region.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12753717.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Chuman H: [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2003 May;30(5):626-33
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma].
  • Malignant fibrous histiocytoma (MFH) is a tumor about which much remains unknown.
  • The cell origin, molecular mechanism of pleomophism and mechanism of pleomorphic change in a cell undergoing malignant change have not been elucidated.
  • MFH-like histological changes are observed in many bone and cartilage sarcomas, and some renal cell carcinomas and malignant lymphomas.
  • MFH has been regarded as one tumor classification from its special histopathological features.
  • In clinical pathological studies these tumors are divided into low-grade fibrous tumors and fibrous histiocytic tumors.
  • With the establishment of molecular biological diagnostic methods, MFH-like histological features can be seen in changes in cellular differentiation of many sarcomas.
  • Patients with MFH often have repeated recurrences before a diagnosis is made, and the tumor is partially resected.
  • The sensitivity of MFH to radiotherapy and chemotherapy is insufficient, and evidence is lacking for adjuvant treatment.
  • Rescue following initial treatment failure is extremely difficult.
  • For treatment of bone and soft tissue sarcoma, a correct diagnosis and initial treatment are extremely important.
  • Many cases need to be accumulated in joint clinical studies across fields according to organ and specialty, and effective treatment method developed.
  • We need to advance the standardization of treatment for MFH, and eliminate wrong initial treatment through the active provision of information.
  • [MeSH-major] Bone Neoplasms. Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Prognosis. Radiotherapy, Adjuvant. Sarcoma / pathology. Sarcoma / surgery. Sarcoma / therapy. Survival Rate

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Iguchi Y, Takahashi H, Yao K, Nakayama M, Nagai H, Okamoto M: Malignant fibrous histiocytoma of the nasal cavity and paranasal sinuses: review of the last 30 years. Acta Otolaryngol Suppl; 2002;(547):75-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the nasal cavity and paranasal sinuses: review of the last 30 years.
  • The clinical and pathologic features of four patients with malignant fibrous histiocytoma of the maxillary sinus were studied.
  • All patients were male, with an age range of 43-71 years at the time of diagnosis.
  • Pathologically, three patients were subclassified with the striform-pleomorphic type of malignant fibrous histiocytoma and one with the myxoid type.
  • All patients were operated on and received various combinations of pre- and postoperative irradiation and intra-arterial chemotherapy given via the temporal artery.
  • Two patients developed local recurrences and died.
  • None of the patients developed locoregional lymph node or systemic metastases.
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / therapy. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Male. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / radiography. Nasal Cavity / surgery. Outcome Assessment (Health Care). Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212601.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 13
  •  go-up   go-down


18. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the abdominal cavity: report of a case.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • We report a case of MFH of the abdominal cavity in a 45-year-old woman who presented with epigastric pain, anorexia, and weight loss.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Saga K, Sato T, Abiko M, Takahashi N, Ikeda E: [A case of primary malignant fibrous histiocytoma of the lung]. Kyobu Geka; 2001 Mar;54(3):191-4
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant fibrous histiocytoma of the lung].
  • A 68-year-old woman presented with a complaint of coughing and chestroentgenography and computed tomography revealed a very large, irregular mass in the left inferior lobe of the lung.
  • The patient received preoperative chemotherapy including cisplatin with vindesine as employed for non-small cell lung cancer.
  • She demonstrated a clinical response after three cycles of the chemotherapy and underwent surgery successfully.
  • A postoperative diagnosis of MFH was made based on the histology of the tumor, which was pleomorphic with a storiform pattern.
  • The patient underwent a further three cycles of postoperative chemotherapy and has remained disease-free for 12 months after tumor resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Benign Fibrous / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244748.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


20. Demiralp B, Ozdemir MT, Erler K, Basbozkurt M: Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases. Acta Orthop Belg; 2007 Jun;73(3):403-7
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases.
  • We report two cases of malignant soft-tissue tumours--one myxoid malignant fibrous histiocytoma and one pleomorphic rhabdomyosarcoma--which were diagnosed in two young adult patients with type 1 neurofibromatosis (NF 1).
  • Both patients were treated with radiotherapy or chemotherapy and surgical intervention.
  • Diagnoses of myxoid malignant fibrous histiocytoma and pleomorphic rhabdomyosarcoma in adult NF 1 patients are exceedingly rare.
  • Thus detection of subtypes of rhabdomyosarcoma and malignant fibrous histiocytoma with immunohistochemistry may be helpful for the management of these tumours among other pleomorphic sarcomas that may occur in type 1 Neurofibromatosis.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / complications. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications. Rhabdomyosarcoma / complications. Soft Tissue Neoplasms

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715736.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


21. Chang RC, Dave SP, Robinson PG: Undifferentiated pleomorphic sarcoma of the parotid gland: a rare pediatric case. Head Neck; 2008 Jul;30(7):970-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated pleomorphic sarcoma of the parotid gland: a rare pediatric case.
  • BACKGROUND: Undifferentiated pleomorphic sarcoma, or malignant fibrous histiocytoma (MFH) of the head and neck is an uncommon malignancy that is exceedingly rare in the pediatric population.
  • Although MFH was once considered the most common soft tissue sarcoma in adults, recently authors have questioned its existence as a distinct pathologic entity.
  • METHODS: In light of this debate, we present a case of MFH with giant cells involving the parotid gland, and we review its pathology.
  • RESULTS: We describe a 6-year-old male with parotid gland MFH.
  • He was treated with a combination of chemotherapy and radiation therapy with a good initial response.
  • CONCLUSION: The classification of MFH has been recently debated.
  • Nevertheless, our case is the second report of pediatric MFH involving the parotid gland.
  • Surgical resection is the preferred treatment, but combined chemoradiation may be necessary in the head and neck region.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Parotid Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Biopsy, Needle. Child. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Staging. Parotid Gland / surgery. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pleomorphic Undifferentiated Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098306.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Shimoyama T, Yoshiya K, Yamato Y, Koike T, Honma K: Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum. Gen Thorac Cardiovasc Surg; 2009 Jun;57(6):310-4
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum.
  • Malignant peripheral nerve sheath tumors (MPNSTs; malignant schwannomas) rarely occur in the anterior mediastinum, and their prognosis is poor.
  • A computed tomography-guided percutaneous needle biopsy revealed only fibrosis.
  • Thereafter, the tumor was diagnosed as a storiform-pleomorphic type of malignant fibrous histiocytoma.
  • No recurrence was found up to 5 years after the second surgery without adjuvant chemotherapy or radiation therapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Mediastinal Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Pericardiectomy. Pneumonectomy. Sternum / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Thoracotomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Jun 1;82(11):2191-203 [9610699.001]
  • [Cites] Chest. 1995 Aug;108(2):574-5 [7634904.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):615-7 [15457164.001]
  • [Cites] J Chin Med Assoc. 2006 Jan;69(1):37-41 [16447925.001]
  • [Cites] Ann Thorac Surg. 2003 May;75(5):1645-8 [12735601.001]
  • [Cites] World J Surg Oncol. 2005 Oct 06;3:65 [16207383.001]
  • [Cites] Monaldi Arch Chest Dis. 2006 Dec;65(4):222-4 [17393668.001]
  • [Cites] Cancer. 1971 May;27(5):1190-201 [5581511.001]
  • [Cites] Respiration. 2000;67(3):346-7 [10867610.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 19533278.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Château MC, Marquès B, Picot V, Guillou L: Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol; 2002 May;26(5):601-16
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group.
  • The clinicopathologic and immunohistochemical features of 63 pleomorphic liposarcomas are presented.
  • Histologically, lesions show a varying combination of lipogenic and nonlipogenic areas characterized by malignant fibrous histiocytoma-like, round cell liposarcoma-like, and/or epithelioid/carcinoma-like features.
  • Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33).
  • Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively.
  • In conclusion, pleomorphic liposarcoma is a rare, often deep-seated and limb-based aggressive and metastasizing neoplasm of late adulthood.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11979090.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


24. Husain EA, Prescott RJ, Haider SA, Al-Mahmoud RW, Zelger BG, Zelger B, Al-Daraji WI: Gallbladder sarcoma: a clinicopathological study of seven cases from the UK and Austria with emphasis on morphological subtypes. Dig Dis Sci; 2009 Feb;54(2):395-400
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on morphological and immunohistochemical features of the PGBS, there were three myxofibrosarcomas (malignant fibrous histiocytoma, MFH, storiform pleomorphic), one leiomyosarcoma (LMS), one angiosarcoma (AS), and two liposarcomas (LS).
  • All patients received cholecystectomy and three received adjuvant chemotherapy.
  • A variety of sarcoma types are found with MFH being the predominant variant.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):91-102 [7123848.001]
  • [Cites] Acta Chir Belg. 2004 Feb;104(1):107-9 [15053476.001]
  • [Cites] Histopathology. 1994 Mar;24(3):269-71 [7726886.001]
  • [Cites] Am J Gastroenterol. 1986 Mar;81(3):202-4 [3513545.001]
  • [Cites] Gut. 1994 Jun;35(6):854-6 [8020820.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]
  • [Cites] Rev Invest Clin. 1989 Apr-Jun;41(2):159-64 [2781178.001]
  • [Cites] Am Surg. 2001 Jul;67(7):714-7 [11450796.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1420-3 [11023105.001]
  • [Cites] Acta Oncol. 1998;37(2):212-4 [9636020.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):812-8 [7055789.001]
  • [Cites] Arch Pathol Lab Med. 2002 Apr;126(4):481-3 [11900579.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(2):225-30 [6289513.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]
  • [Cites] Indian J Pathol Microbiol. 1993 Jan;36(1):78-80 [8354563.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):323-33 [6731662.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Histopathology. 1987 Feb;11(2):209-14 [2437004.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):919-27 [7260842.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1298-305 [8276377.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):609-11 [17768664.001]
  • [Cites] Ann Diagn Pathol. 1999 Apr;3(2):75-80 [10196386.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):70-83 [17193820.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Arch Pathol Lab Med. 1995 Dec;119(12):1173-6 [7503670.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):822-5 [15985238.001]
  • [Cites] Surg Today. 2002;32(1):81-5 [11871825.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1598-604 [17895763.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1373-81 [16160481.001]
  • [Cites] Mil Med. 1992 Oct;157(10):559-61 [1454184.001]
  • (PMID = 18618258.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Collini P, Sorensen PH, Patel S, Blay JY, Issels RD, Maki RG, Eriksson M, del Muro XG: Sarcomas with spindle cell morphology. Semin Oncol; 2009 Aug;36(4):324-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the days before the term "high-grade undifferentiated pleomorphic sarcoma" came into use, one of the most common sarcoma diagnoses was "malignant fibrous histiocytoma," and before that, in an era before immunohistochemistry, "fibrosarcoma" was used to describe most sarcomas.
  • As a very broad generalization, sarcomas with a spindle cell microscopic morphology occur in adults and are treated primarily with surgery and often adjuvant or neoadjuvant radiation as primary therapy.
  • In comparison to small round cell sarcomas such as Ewing sarcoma, the use of adjuvant chemotherapy remains controversial, and the sensitivity of these tumors to chemotherapy in the metastatic setting is highly variable.
  • [MeSH-minor] Chemotherapy, Adjuvant. Fibrosarcoma / genetics. Fibrosarcoma / pathology. Gene Fusion. Heat-Shock Response. Humans. Hyperthermia, Induced. Protein Kinase Inhibitors / therapeutic use. Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664493.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 62
  •  go-up   go-down


27. Ravi V, Benjamin RS: Systemic therapy for cardiac sarcomas. Methodist Debakey Cardiovasc J; 2010 Jul-Sep;6(3):57-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for cardiac sarcomas.
  • Most frequently, the histologies are angiosarcoma and high-grade pleomorphic unclassified sarcoma (formerly called MFH or malignant fibrous histiocytoma).
  • Conventional wisdom indicates that soft-tissue sarcomas are poorly responsive to chemotherapy.
  • Attempts to concentrate on the local problem only with therapies up to and including cardiac transplantation have been unsuccessful due to the high rate of fatal metastatic disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Heart Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20834213.001).
  • [ISSN] 1947-6094
  • [Journal-full-title] Methodist DeBakey cardiovascular journal
  • [ISO-abbreviation] Methodist Debakey Cardiovasc J
  • [Language] eng
  • [Publication-type] Journal Article; Portraits
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement